Most cases of Parkinson’s disease are not directly inherited. About 10 to 15 percent of people with Parkinson’s have a family history of the condition, while the remaining 85 to 90 percent develop it with no clear genetic link. That said, genetics do play a role, sometimes a significant one, and the picture gets more complex when you look at specific genes, age of onset, and how genes interact with environmental factors.
How Family History Affects Your Risk
Having a first-degree relative (a parent or sibling) with Parkinson’s roughly doubles your risk compared to the general population. A community-based study found that first-degree relatives of Parkinson’s patients were 2.3 times as likely to develop the disease as relatives of people without it. But “doubled risk” sounds more alarming than it is in absolute terms. The cumulative chance of developing Parkinson’s by age 75 was about 2 percent for those with an affected family member, compared to 1 percent for those without. So even with a parent or sibling who has the disease, your likelihood of developing it yourself remains low. The risk was similar whether it was a sibling or a parent who was affected.
Genes Linked to Parkinson’s
Researchers have identified more than 500 distinct genetic variants across five major genes tied to familial Parkinson’s. These genes fall into two categories based on how they’re passed down.
Two genes cause Parkinson’s through a dominant inheritance pattern, meaning you only need one copy of the mutated gene (from one parent) to be affected. The first, SNCA, produces a protein involved in how brain cells release chemical signals to each other. When this gene is mutated, the protein misfolds and clumps together, forming the characteristic deposits found in the brains of Parkinson’s patients. The second, LRRK2, is the most common genetic cause of Parkinson’s overall. Its exact function isn’t fully understood, but it appears to act as both a signaling enzyme and a structural protein inside cells.
Three genes cause Parkinson’s through a recessive pattern, meaning you need two copies of the mutation (one from each parent) to develop the disease. These are Parkin, PINK1, and DJ-1. All three are involved in protecting the cell’s energy-producing machinery (mitochondria) from damage. Parkin tags broken-down proteins for disposal and helps maintain healthy mitochondria. PINK1 works alongside Parkin to monitor mitochondria under stress and flag damaged ones for removal. DJ-1 acts as a sensor for harmful oxidative damage inside cells, particularly the kind caused by the brain chemical dopamine.
Early-Onset Parkinson’s Has a Stronger Genetic Link
The younger someone is when they develop Parkinson’s, the more likely a genetic mutation is involved. Among people diagnosed before age 30, about 41 percent carry a known mutation. For those diagnosed between ages 31 and 50, that drops to around 15 percent. By the time you’re looking at the typical age of diagnosis (over 60), genetic mutations explain a much smaller share of cases. This is why genetic testing is most often considered for people who develop symptoms unusually early or who have multiple affected family members.
Some Populations Carry Higher Genetic Risk
Certain ethnic groups have notably higher rates of specific Parkinson’s-related mutations. The LRRK2 G2019S mutation, the single most common genetic cause of Parkinson’s worldwide, shows up in about 1 percent of all sporadic cases and 4 percent of familial ones. But among Ashkenazi Jewish patients with Parkinson’s, 14 to 19 percent carry this mutation. Among North African Berbers with Parkinson’s, the rate is even higher at roughly 39 percent. These population-specific patterns mean that ancestry is one factor doctors consider when evaluating whether genetic testing might be informative.
Your Genes Can Shape How the Disease Progresses
Not all genetic forms of Parkinson’s behave the same way. People who carry mutations in the GBA gene (which affects how cells break down certain fats) tend to experience faster cognitive decline and faster worsening of movement symptoms compared to both people with LRRK2 mutations and those with no identified genetic cause. LRRK2 carriers, by contrast, often have a milder course. An interesting finding: people who carry both LRRK2 and GBA mutations tend to follow a trajectory that looks more like LRRK2-only Parkinson’s, suggesting LRRK2 may have a protective influence that partially offsets GBA’s more aggressive effects.
The recessive forms caused by Parkin, PINK1, and DJ-1 typically cause earlier symptom onset but present as “pure” parkinsonism, meaning the core movement symptoms without many of the additional cognitive or psychiatric features that can accompany other forms.
Genes and Environment Work Together
For the vast majority of people with Parkinson’s, the disease likely results from a combination of genetic susceptibility and environmental exposures. Pesticide exposure is one of the most studied environmental risk factors, and researchers have found suggestive evidence that certain gene variants can change how much pesticide exposure affects your risk. For example, variants in genes involved in DNA repair and cellular stress response appear to modify whether pesticide exposure raises or lowers risk. In some cases, a gene variant has no effect on Parkinson’s risk in people who weren’t exposed to pesticides but increases risk in those who were.
This gene-environment interplay helps explain why Parkinson’s can cluster in families without following a clear inheritance pattern. Relatives share not just genes but often similar environments, diets, and occupational exposures. Separating those influences is one of the ongoing challenges in understanding the disease.
What Genetic Testing Can Tell You
Genetic testing for Parkinson’s is available, but its practical value depends on your situation. It’s most useful for people diagnosed before age 50, those with multiple affected family members, or those from high-risk ethnic backgrounds like Ashkenazi Jewish or North African Berber populations. For the average person diagnosed with Parkinson’s in their 60s or 70s with no family history, testing is less likely to reveal a clear genetic cause.
Knowing your genetic status can sometimes guide treatment decisions, since gene-targeted therapies are being developed for LRRK2 and GBA carriers specifically. It can also help family members understand their own risk. But a negative test doesn’t rule out a genetic contribution, since many risk-influencing variants haven’t been identified yet. And a positive result for most mutations doesn’t guarantee the disease will develop, since many of these mutations have incomplete “penetrance,” meaning not everyone who carries them actually gets sick.